1. Background
2. Objectives
3. Methods
3.1. Nanostructured Lipid Carriers Preparation
3.2. Determination of Particle Size and Zeta Potential
3.3. Determination of Encapsulation Efficiency
3.4. Investigation of Morphology of Lipid Nanoparticles
3.5. Fourier-Transform Infrared Spectroscopy
3.6. Preparation of 0.5 McFarland Standard
3.7. Preparation of Bacteria
3.8. Evaluation of Antimicrobial Activity by Cup Plate Method
3.9. Measurement of Minimum Inhibitory Concentration by Microdilution Technique
3.10. Assessment of Minimum Bactericidal Concentration
3.11. Microtiter Plate Assay to Assess Biofilm Elimination Potential
3.12. Statistical Analysis
4. Results
4.1. Experimental Design
| Levels | -1 | 0 | +1 |
|---|---|---|---|
| Lipid (w/w %) | 3 | 4 | 5 |
| Lipid ratio (stearic acid/lavender oil) | 3 | 4 | 5 |
| Surfactant (w/w %) | 1 | 2 | 3 |
| Feed ratio of surfactants | 0.5 | 1.25 | 2 |
| Drug (w/w %) | 1 | 3 | 5 |
| Run | Lipid (w/w %) | Lipid Ratio b | Surfactant (w/w %) | Feed Ratio of Surfactant (%) c | Piperine (w/w %) | Size (nm) | Zeta Potential (mV) | Polydispersity |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.00 | 4.00 | 2.00 | 1.25 | 5.00 | 344 ± 8.22 | -23.2 ± 6.91 | 0.401 ± 0.054 |
| 2 | 4.00 | 4.00 | 2.00 | 1.25 | 3.00 | 357 ± 7.34 | -21.7 ± 7.32 | 0.411 ± 0.061 |
| 3 | 4.00 | 4.00 | 2.00 | 1.25 | 1.00 | 343 ± 6.51 | -22.8 ± 5.32 | 0.390 ± 0.032 |
| 4 | 4.00 | 4.00 | 2.00 | 1.25 | 3.00 | 359 ± 6.87 | -21.3 ± 3.28 | 0.390 ± 0.045 |
| 5 | 4.00 | 4.00 | 3.00 | 1.25 | 3.00 | 318 ± 3.82 | -22.3 ± 4.38 | 0.321 ± 0.081 |
| 6 | 3.00 | 4.00 | 2.00 | 1.25 | 3.00 | 223 ± 6.21 | -23.4 ± 2.87 | 0.290 ± 0.032 |
| 7 | 4.00 | 3.00 | 2.00 | 1.25 | 3.00 | 322 ± 5.75 | -21.8 ± 5.37 | 0.332 ± 0.058 |
| 8 | 4.00 | 4.00 | 2.00 | 0.50 | 3.00 | 344 ± 4.37 | -21.2 ± 4.61 | 0.391 ± 0.067 |
| 9 | 5.00 | 5.00 | 1.00 | 2.00 | 1.00 | 484 ± 9.11 | -22.3 ± 3.65 | 0.530 ± 0.028 |
| 10 | 4.00 | 5.00 | 2.00 | 1.25 | 3.00 | 384 ± 8.15 | -23.2 ± 9.10 | 0.933 ± 0.034 |
| 11 | 4.00 | 4.00 | 2.00 | 2.00 | 3.00 | 370 ± 7.21 | -21.5 ± 8.23 | 0.315 ± 0.051 |
| 12 | 3.00 | 5.00 | 3.00 | 2.00 | 1.00 | 187 ± 4.14 | -23.1 ± 5.38 | 0.241 ± 0.068 |
| 13 | 5.00 | 5.00 | 3.00 | 0.50 | 1.00 | 454 ± 4.21 | -21.9 ± 5.39 | 0.490 ± 0.092 |
| 14 | 3.00 | 5.00 | 1.00 | 2.00 | 5.00 | 245 ± 3.78 | -22.1 ± 3.84 | 0.290 ± 0.085 |
| 15 | 4.00 | 4.00 | 2.00 | 1.25 | 3.00 | 353 ± 2.91 | -21.2 ± 4.37 | 0.392 ± 0.075 |
| 16 | 5.00 | 3.00 | 1.00 | 2.00 | 5.00 | 465 ± 2.15 | -22.5 ± 4.93 | 0.510 ± 0.073 |
| 17 | 5.00 | 5.00 | 1.00 | 0.50 | 5.00 | 473 ± 8.17 | -21.9 ± 5.81 | 0.503 ± 0.019 |
| 18 | 3.00 | 3.00 | 1.00 | 0.50 | 1.00 | 204 ± 9.2 | -22.8 ± 8.94 | 0.315 ± 0.082 |
| 19 | 4.00 | 4.00 | 2.00 | 1.25 | 3.00 | 360 ± 8.72 | -22.2 ± 7.34 | 0.395 ± 0.065 |
| 20 | 3.00 | 5.00 | 3.00 | 0.50 | 5.00 | 210 ± 6.94 | -21.8 ± 5.87 | 0.295 ± 0.028 |
| 21 | 4.00 | 4.00 | 1.00 | 1.25 | 3.00 | 394 ± 4.31 | -22.7 ± 9.45 | 0.405 ± 0.053 |
| 22 | 5.00 | 3.00 | 3.00 | 0.50 | 5.00 | 437 ± 5.53 | -21.3 ± 8.35 | 0.483 ± 0.038 |
| 23 | 5.00 | 3.00 | 3.00 | 2.00 | 1.00 | 424±5.27 | -22.4 ± 7.11 | 0.495 ± 0.042 |
| 24 | 3.00 | 3.00 | 3.00 | 2.00 | 5.00 | 185 ± 4.38 | -22.1 ± 8.15 | 0.280 ± 0.058 |
| 25 | 4.00 | 4.00 | 2.00 | 1.25 | 3.00 | 356 ± 7.21 | -21.9 ± 6.21 | 0.390 ± 0.092 |
| 26 | 5.00 | 4.00 | 2.00 | 1.25 | 3.00 | 472 ± 5.33 | -22.7 ± 6.52 | 0.580 ± 0.037 |
a Values are expressed as mean ± SD unless otherwise indicated.
b Stearic acid/lavender oil.
c Span 80/Tween.
| Variables | Experiment Value | Predicted Value | Error (%) |
|---|---|---|---|
| Size (nm) | 187 | 179 | 4.2 |
| PDI | 0.241 | 0.234 | 2.9 |
| Zeta potential (mV) | -23.1 | -23.4 | 1.2 |
Abbreviation: PDI, Polydispersity Index.
4.2. Transmission Electron Microscopy Image Results
4.3. Fourier-Transform Infrared Spectrum of Piperine
4.4. Encapsulation Percentage
4.5. Evaluation of Diameter of the Inhibition Zone
| Formulation | NLC-Pip | NLC Without Piperine | Free Piperine | Gentamicin |
|---|---|---|---|---|
| The diameter of inhibition zone | 17 ± 2.3 | 0.0 ± 0.0 | 19 ± 1.1 | 20 ± 1.8 |
Abbreviations: NLC-Pip, nanostructured lipid carriers containing piperine; NLC, nanostructured lipid carrier.
a Values are reported as mean ± SD.
4.6. Assessment of the Minimum Inhibitory Concentration and Minimum Bactericidal Concentration
| Tests | NLC-Pip | Free Piperine |
|---|---|---|
| MIC (µg/mL) | 40 | 40 |
| MBC (µg/mL) | 80 | 80 |
Abbreviation: MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; NLC-Pip, nanostructured lipid carriers containing piperine.



